Biodexa Pharmaceuticals Plc
BDRX evidence brief
What we can confirm
- Market Cap:
- $1.2M
What it means
What to watch
Prepared research question
What matters most for BDRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BDRX
Biodexa Pharmaceuticals Plc (BDRX) is a UK-based clinical-stage biotech developing small-molecule therapeutics for oncology and metabolic diseases, with a focus on advancing assets to proof-of-concept before partnering.
Key risk: Financing risk
Market Cap
$1.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Biodexa Pharmaceuticals Plc (BDRX) is a UK-based clinical-stage biotech developing small-molecule therapeutics for oncology and metabolic diseases, with a focus on advancing assets to proof-of-concept before partnering.
- eRapa Phase 2 trial in colon polyps showed 75% non-progression at 12 months and a 17% median reduction in polyp burden [sec · filed 2025-04-11].
- MTX240, a molecular glue candidate in-licensed from Otsuka in February 2026, is planned for a Phase 1b/2a study in GIST by year-end 2026 [sec · filed 2026-03-27].
- Tolimidone, in-licensed December 2023, is in a Phase 2a investigator-initiated trial at the University of Alberta for Type 1 diabetes [sec · filed 2026-03-27].
- The company relies on $20.0 million in CPRIT grant funding to develop eRapa through Phase 3 to potential registration [sec · filed 2026-03-27].
- Biodexa does not intend to establish its own manufacturing; it uses GMP-certified contract manufacturers for clinical supplies [sec · filed 2025-04-11].
What works
- eRapa demonstrated a statistically significant 24% reduction in total polyp burden at six months (p=0.04) with 97% of patients remaining on treatment [sec · filed 2025-04-11].
- The company has secured $20.0 million in non-dilutive grant funding from CPRIT to support eRapa through Phase 3 [sec · filed 2026-03-27].
- Biodexa's strategy of developing assets to proof-of-concept before partnering reduces its own later-stage financial risk [sec · filed 2026-03-27].
What to weigh
- The company acknowledges it requires additional financing and may not be able to continue as a going concern [sec · filed 2026-03-27].
- Even if product candidates are approved, Biodexa may not become profitable and may need further funding to sustain operations [sec · filed 2026-03-27].
- The company has no internal manufacturing capabilities and relies entirely on external contract manufacturers [sec · filed 2025-04-11].
- Clinical trial results are uncertain; for example, in the MTX110 Phase 1 trial for glioblastoma, two of the first four patients had deceased [sec · filed 2025-04-11].
From the filings
Quoted directly from source documents.
eRapa Phase 2 12-month results showed 75% non-progression and 17% median polyp burden reduction
“Overall, 21 out of 28 patients, or 75%, were deemed to be non-progressors at 12 months, with a median reduction in polyp burden of 17%.”
SEC filings · April 11, 2025
MTX240 in-licensed from Otsuka in February 2026 for GIST
“MTX240 was in-licensed from Otsuka in February 2026 and we intend to develop it for GIST.”
SEC filings · March 27, 2026
Company requires additional financing and may not continue as a going concern
“our requirement for additional financing and our ability to continue as a going concern;”
SEC filings · March 27, 2026
eRapa Phase 2 six-month results showed 24% reduction in polyp burden (p=0.04)
“a significant 24% reduction in the total polyp burden at six months compared with baseline (p=0.04)”
SEC filings · April 11, 2025
Risks & what to watch (4)›
Key risks
- Financing risk — Company states it requires additional financing and may not be able to continue as a going concern [sec · filed 2026-03-27].
- Profitability uncertainty — Even with approved products, Biodexa may not become profitable and may need further funding [sec · filed 2026-03-27].
- Clinical trial failure — Early-stage trials (e.g., MTX110) have shown patient deaths; results are unpredictable [sec · filed 2025-04-11].
- Dependence on partners — Company relies on contract manufacturers and plans to partner for later-stage development, creating execution risk [sec · filed 2025-04-11].
What to watch
- eRapa Phase 3 readout expected in Q3 2026 after enrolling all 166 patients [sec · filed 2026-03-27].
- First patient dosed in MTX240 Phase 1b/2a study for GIST targeted by year-end 2026 [sec · filed 2026-03-27].
- Tolimidone Phase 2a investigator-initiated trial results for Type 1 diabetes [sec · filed 2026-03-27].
- Company's ability to secure additional financing to sustain operations beyond current cash runway [sec · filed 2026-03-27].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run Biodexa Pharmaceuticals Plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Biodexa Pharmaceuticals Plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$93
| Holder | Shares | Value |
|---|---|---|
| sbi securities co., ltd. | 151 | $93 |
Short Interest
as of Apr 28, 2026- % of float
- 6.3%
- Days to cover
- 0.0
- Shares short
- 40,924
- Daily short volume (Jul 15, 2026)
- 53.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BDRX short interestFrequently asked questions
What is the AI investment thesis for Biodexa Pharmaceuticals Plc?
Biodexa Pharmaceuticals Plc (BDRX) is a UK-based clinical-stage biotech developing small-molecule therapeutics for oncology and metabolic diseases, with a focus on advancing assets to proof-of-concept before partnering.
Who is the CEO of Biodexa Pharmaceuticals Plc?
Mr. Stephen Anthony Stamp is the chief executive officer of Biodexa Pharmaceuticals Plc (BDRX).
Where is Biodexa Pharmaceuticals Plc headquartered?
Biodexa Pharmaceuticals Plc (BDRX) is headquartered in Cardiff, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.